Woodcock Ashley, Forster Louise, Matthews Edward, Martin Jeannett, Letley Louise, Vickers Madge, Britton John, Strachan David, Howarth Peter, Altmann Daniel, Frost Christopher, Custovic Adnan
South Manchester Academic Group, University of Manchester, North West Lung Centre, Wythenshawe Hospital, Manchester, United Kingdom.
N Engl J Med. 2003 Jul 17;349(3):225-36. doi: 10.1056/NEJMoa023175.
The effectiveness of avoidance of house-dust-mite allergen (Dermatophagoides pteronyssinus 1 [Der p1]) in the management of asthma is uncertain.
We conducted a double-blind, randomized, placebo-controlled study of allergen-impermeable bed covers involving 1122 adults with asthma. The primary outcomes were the mean morning peak expiratory flow rate over a four-week period during the run-in phase and at six months and the proportion of patients who discontinued inhaled corticosteroid therapy as part of a phased-reduction program during months 7 through 12. Der p1 was measured in mattress dust in a 10 percent random subsample of homes at entry and at 6 and 12 months.
The prevalence of sensitivity to dust-mite allergen was 65.4 percent in the group supplied with allergen-impermeable bed covers (active-intervention group) and 65.1 percent in the control group supplied with non-impermeable bed covers. The concentration of Der p1 in mattress dust was significantly lower in the active-intervention group at 6 months (geometric mean, 0.58 microg per gram vs. 1.71 microg per gram in the control group; P=0.01) but not at 12 months (1.05 microg per gram vs. 1.64 microg per gram; P=0.74). The mean morning peak expiratory flow rate improved significantly in both groups (from 410.7 to 419.1 liters per minute in the active-intervention group, P<0.001 for the change; and from 417.8 to 427.4 liters per minute in the control group, P<0.001 for the change). After adjustment for base-line differences (by analysis of covariance), there was no significant difference between the groups in the peak expiratory flow rate at six months (difference in means, active-intervention group vs. control group, -1.6 liters per minute [95 percent confidence interval, -5.9 to 2.7] among all patients [P=0.46] and -1.5 liters per minute [95 percent confidence interval, -6.9 to 3.9] among mite-sensitive patients [P=0.59]). There was no significant difference between the groups in the proportion in whom complete cessation of inhaled corticosteroid therapy was achieved (17.4 percent in the active-intervention group and 17.1 percent in the control group) or in the mean reduction in steroid dose, either among all patients or among mite-sensitive patients.
Allergen-impermeable covers, as a single intervention for the avoidance of exposure to dust-mite allergen, seem clinically ineffective in adults with asthma.
避免接触屋尘螨过敏原(粉尘螨1 [Der p1])在哮喘管理中的有效性尚不确定。
我们进行了一项双盲、随机、安慰剂对照研究,研究对象为1122名成年哮喘患者,使用防过敏原床罩。主要结局指标为导入期、6个月时四周内的平均晨起呼气峰值流速,以及在第7至12个月期间作为逐步减量计划一部分而停用吸入性糖皮质激素治疗的患者比例。在入组时、6个月和12个月时,对10%的随机抽取家庭的床垫灰尘进行Der p1检测。
使用防过敏原床罩的组(主动干预组)对尘螨过敏原敏感的患病率为65.4%,使用不防过敏原床罩的对照组为65.1%。主动干预组在6个月时床垫灰尘中Der p1的浓度显著低于对照组(几何平均数,0.58微克/克 vs. 对照组的1.71微克/克;P = 0.01),但在12个月时无显著差异(1.05微克/克 vs. 1.64微克/克;P = 0.74)。两组的平均晨起呼气峰值流速均显著改善(主动干预组从410.7升/分钟增至419.1升/分钟,变化P<0.001;对照组从417.8升/分钟增至427.4升/分钟,变化P<0.001)。在对基线差异进行调整后(通过协方差分析),两组在6个月时的呼气峰值流速无显著差异(所有患者中,主动干预组与对照组的均值差为-1.6升/分钟[95%置信区间,-5.9至2.7] [P = 0.46],对尘螨敏感的患者中为-1.5升/分钟[95%置信区间,-6.9至3.9] [P = 0.59])。两组在实现完全停用吸入性糖皮质激素治疗的患者比例(主动干预组为17.4%,对照组为17.1%)或激素剂量的平均减少量方面,在所有患者或对尘螨敏感的患者中均无显著差异。
作为避免接触尘螨过敏原的单一干预措施,防过敏原床罩对成年哮喘患者似乎临床无效。